Skip to main content
Top
Published in: World Journal of Surgery 6/2012

01-06-2012

Preoperative 18F-FDG Uptake is Strongly Correlated with Malignancy, Weiss Score, and Molecular Markers of Aggressiveness in Adrenal Cortical Tumors

Authors: Lucile Gust, David Taieb, Arnault Beliard, Anne Barlier, Isabelle Morange, Catherine de Micco, Jean-François Henry, Frederic Sebag

Published in: World Journal of Surgery | Issue 6/2012

Login to get access

Abstract

Background

Adrenal incidentaloma are frequent in the general population. It can be difficult to diagnose adrenocortical carcinomas among them, even with the progress of imaging techniques. We studied the results of PET-FDG in the diagnosis of such tumours.

Methods

We studied patients referred to the Department of Endocrine Surgery at La Timone Hospital, Marseilles, France, between June 2006 and October 2010 for adrenal tumours. All patients underwent a complete work-up (biological tests and imagery), completed with PET-FDG. We compared the results of PET-FDG and molecular analysis with Weiss score and clinical follow-up. We calculated correlations with the Pearson test.

Results

A total of 51 patients were studied. We found that PET-FDG had a sensitivity of 95% and specificity of 97% for the diagnosis of adrenocortical carcinoma. The correlation between PET-FDG and Weiss score was 77% (P ≤ 0.0001). Molecular analyses were correlated as well with Weiss score and malignancy (P < 0.05).

Conclusions

The nature of atypical adrenal masses can be difficult to define during preoperative investigations. For undetermined tumours smaller than 6 cm, characterization with PET-FDG can be one more diagnostic argument pointing to malignancy. It could potentially change the therapeutic strategy and surgical management. In our experience, molecular analyses are available after surgery and have less impact on the therapeutic strategy than PET-FDG. Preoperative PET-FDG can be an asset in the management of adrenal incidentaloma and adrenocortical carcinoma.
Literature
1.
go back to reference Bovio S, Cataldi A, Reimondo G et al (2006) Prevalence of adrenal incidentaloma in a contemporary computerized tomography series. J Endocrinol Invest 29:298–302PubMed Bovio S, Cataldi A, Reimondo G et al (2006) Prevalence of adrenal incidentaloma in a contemporary computerized tomography series. J Endocrinol Invest 29:298–302PubMed
2.
go back to reference Grumbach MM, Biller BM, Braunstein GD et al (2003) Management of the clinically inapparent adrenal mass (“incidentaloma”). Ann Intern Med 138:424–429PubMed Grumbach MM, Biller BM, Braunstein GD et al (2003) Management of the clinically inapparent adrenal mass (“incidentaloma”). Ann Intern Med 138:424–429PubMed
3.
go back to reference Mansmann G, Lau J, Balk E et al (2004) The clinically inapparent adrenal mass: update in diagnosis and management. Endocr Rev 25:309–340PubMedCrossRef Mansmann G, Lau J, Balk E et al (2004) The clinically inapparent adrenal mass: update in diagnosis and management. Endocr Rev 25:309–340PubMedCrossRef
4.
go back to reference Fassnacht M, Allolio B (2009) Clinical management of adrenocortical carcinoma. Best Pract Res Clin Endocrinol Metab 23:273–289PubMedCrossRef Fassnacht M, Allolio B (2009) Clinical management of adrenocortical carcinoma. Best Pract Res Clin Endocrinol Metab 23:273–289PubMedCrossRef
5.
go back to reference Ilias I, Sahdev A, Reznek RH et al (2007) The optimal imaging of adrenal tumours: a comparison of different methods. Endocr Relat Cancer 14:587–599PubMedCrossRef Ilias I, Sahdev A, Reznek RH et al (2007) The optimal imaging of adrenal tumours: a comparison of different methods. Endocr Relat Cancer 14:587–599PubMedCrossRef
6.
go back to reference Mayo-Smith WW, Boland GW, Noto RB et al (2001) State-of-the-art adrenal imaging. Radiographics 21:995–1012PubMed Mayo-Smith WW, Boland GW, Noto RB et al (2001) State-of-the-art adrenal imaging. Radiographics 21:995–1012PubMed
7.
go back to reference Downey RJ, Akhurst T, Gonen M et al (2004) Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol 22:3255–3260PubMedCrossRef Downey RJ, Akhurst T, Gonen M et al (2004) Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol 22:3255–3260PubMedCrossRef
8.
go back to reference Rohren EM, Turkington TG, Coleman RE (2004) Clinical applications of PET in oncology. Radiology 231:305–332PubMedCrossRef Rohren EM, Turkington TG, Coleman RE (2004) Clinical applications of PET in oncology. Radiology 231:305–332PubMedCrossRef
9.
go back to reference Schwartz DL, Rajendran J, Yueh B et al (2004) FDG-PET prediction of head and neck squamous cell cancer outcomes. Arch Otolaryngol Head Neck Surg 130:1361–1367PubMedCrossRef Schwartz DL, Rajendran J, Yueh B et al (2004) FDG-PET prediction of head and neck squamous cell cancer outcomes. Arch Otolaryngol Head Neck Surg 130:1361–1367PubMedCrossRef
10.
go back to reference Tessonnier L, Sebag F, Palazzo FF et al (2008) Does 18F-FDG PET/CT add diagnostic accuracy in incidentally identified non-secreting adrenal tumours? Eur J Nucl Med Mol Imaging 35:2018–2025PubMedCrossRef Tessonnier L, Sebag F, Palazzo FF et al (2008) Does 18F-FDG PET/CT add diagnostic accuracy in incidentally identified non-secreting adrenal tumours? Eur J Nucl Med Mol Imaging 35:2018–2025PubMedCrossRef
11.
go back to reference Weiss LM, Medeiros LJ, Vickery AL Jr (1989) Pathologic features of prognostic significance in adrenocortical carcinoma. Am J Surg Pathol 13:202–206PubMedCrossRef Weiss LM, Medeiros LJ, Vickery AL Jr (1989) Pathologic features of prognostic significance in adrenocortical carcinoma. Am J Surg Pathol 13:202–206PubMedCrossRef
12.
go back to reference Libe R, Bertherat J (2005) Molecular genetics of adrenocortical tumours, from familial to sporadic diseases. Eur J Endocrinol 153:477–487PubMedCrossRef Libe R, Bertherat J (2005) Molecular genetics of adrenocortical tumours, from familial to sporadic diseases. Eur J Endocrinol 153:477–487PubMedCrossRef
13.
go back to reference Libe R, Fratticci A, Bertherat J (2007) Adrenocortical cancer: pathophysiology and clinical management. Endocr Relat Cancer 14:13–28PubMedCrossRef Libe R, Fratticci A, Bertherat J (2007) Adrenocortical cancer: pathophysiology and clinical management. Endocr Relat Cancer 14:13–28PubMedCrossRef
14.
go back to reference Bilimoria KY, Shen WT, Elaraj D et al (2008) Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. Cancer 113:3130–3136PubMedCrossRef Bilimoria KY, Shen WT, Elaraj D et al (2008) Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. Cancer 113:3130–3136PubMedCrossRef
16.
go back to reference Fassnacht M, Johanssen S, Quinkler M et al (2009) Limited prognostic value of the 2004 International Union against cancer staging classification for adrenocortical carcinoma: proposal for a revised TNM classification. Cancer 115:243–250PubMedCrossRef Fassnacht M, Johanssen S, Quinkler M et al (2009) Limited prognostic value of the 2004 International Union against cancer staging classification for adrenocortical carcinoma: proposal for a revised TNM classification. Cancer 115:243–250PubMedCrossRef
17.
go back to reference Allolio B, Fassnacht M (2006) Clinical review: adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab 91:2027–2037PubMedCrossRef Allolio B, Fassnacht M (2006) Clinical review: adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab 91:2027–2037PubMedCrossRef
18.
go back to reference Sperti C, Pasquali C, Chierichetti F et al (2003) 18-Fluorodeoxyglucose positron emission tomography in predicting survival of patients with pancreatic carcinoma. J Gastrointest Surg 7:953–959 (discussion 960)PubMedCrossRef Sperti C, Pasquali C, Chierichetti F et al (2003) 18-Fluorodeoxyglucose positron emission tomography in predicting survival of patients with pancreatic carcinoma. J Gastrointest Surg 7:953–959 (discussion 960)PubMedCrossRef
19.
go back to reference Mackie GC, Shulkin BL, Ribeiro RC et al (2006) Use of [18F]fluorodeoxyglucose positron emission tomography in evaluating locally recurrent and metastatic adrenocortical carcinoma. J Clin Endocrinol Metab 91:2665–2671PubMedCrossRef Mackie GC, Shulkin BL, Ribeiro RC et al (2006) Use of [18F]fluorodeoxyglucose positron emission tomography in evaluating locally recurrent and metastatic adrenocortical carcinoma. J Clin Endocrinol Metab 91:2665–2671PubMedCrossRef
20.
go back to reference Yun M, Kim W, Alnafisi N et al (2001) 18F-FDG PET in characterizing adrenal lesions detected on CT or MRI. J Nucl Med 42:1795–1799PubMed Yun M, Kim W, Alnafisi N et al (2001) 18F-FDG PET in characterizing adrenal lesions detected on CT or MRI. J Nucl Med 42:1795–1799PubMed
21.
go back to reference Boland GW, Blake MA, Holalkere NS et al (2009) PET/CT for the characterization of adrenal masses in patients with cancer: qualitative versus quantitative accuracy in 150 consecutive patients. AJR Am J Roentgenol Rad Ther 192:956–962CrossRef Boland GW, Blake MA, Holalkere NS et al (2009) PET/CT for the characterization of adrenal masses in patients with cancer: qualitative versus quantitative accuracy in 150 consecutive patients. AJR Am J Roentgenol Rad Ther 192:956–962CrossRef
22.
go back to reference Leboulleux S, Dromain C, Bonniaud G et al (2006) Diagnostic and prognostic value of 18-fluorodeoxyglucose positron emission tomography in adrenocortical carcinoma: a prospective comparisonn with computed tomography. J Clin Endocrinol Metab 91:920–925PubMedCrossRef Leboulleux S, Dromain C, Bonniaud G et al (2006) Diagnostic and prognostic value of 18-fluorodeoxyglucose positron emission tomography in adrenocortical carcinoma: a prospective comparisonn with computed tomography. J Clin Endocrinol Metab 91:920–925PubMedCrossRef
23.
go back to reference Tenenbaum F, Groussin L, Foehrenbach H et al (2004) 18F-fluorodeoxyglucose positron emission tomography as a diagnostic tool for malignancy of adrenocortical tumours? Preliminary results in 13 consecutive patients. Eur J Endocrinol 150:789–792PubMedCrossRef Tenenbaum F, Groussin L, Foehrenbach H et al (2004) 18F-fluorodeoxyglucose positron emission tomography as a diagnostic tool for malignancy of adrenocortical tumours? Preliminary results in 13 consecutive patients. Eur J Endocrinol 150:789–792PubMedCrossRef
24.
go back to reference Brunaud L, Kebebew E, Sebag F et al (2006) Observation or laparoscopic adrenalectomy for adrenal incidentaloma? A surgical decision analysis. Med Sci Monit 12:CR355–CR362PubMed Brunaud L, Kebebew E, Sebag F et al (2006) Observation or laparoscopic adrenalectomy for adrenal incidentaloma? A surgical decision analysis. Med Sci Monit 12:CR355–CR362PubMed
26.
go back to reference Schteingart DE, Doherty GM, Gauger PG et al (2005) Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocr Relat Cancer 12:667–680PubMedCrossRef Schteingart DE, Doherty GM, Gauger PG et al (2005) Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocr Relat Cancer 12:667–680PubMedCrossRef
Metadata
Title
Preoperative 18F-FDG Uptake is Strongly Correlated with Malignancy, Weiss Score, and Molecular Markers of Aggressiveness in Adrenal Cortical Tumors
Authors
Lucile Gust
David Taieb
Arnault Beliard
Anne Barlier
Isabelle Morange
Catherine de Micco
Jean-François Henry
Frederic Sebag
Publication date
01-06-2012
Publisher
Springer-Verlag
Published in
World Journal of Surgery / Issue 6/2012
Print ISSN: 0364-2313
Electronic ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-011-1374-2

Other articles of this Issue 6/2012

World Journal of Surgery 6/2012 Go to the issue